Details for Patent: 8,524,733

Which drugs does patent 8,524,733 protect, and when does it expire?

Patent 8,524,733 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.

Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in nineteen countries.

Summary for Patent: 8,524,733

Title:	Benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract:	The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. ##STR00001##
Inventor(s):	Gant; Thomas G. (Carlsbad, CA), Shahbaz; Manoucherhr M. (Escondido, CA)
Assignee:	Auspex Pharmaceuticals (La Jolla, CA)
Application Number:	12/562,621
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,524,733
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,524,733

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-001	Feb 17, 2023		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-002	Feb 17, 2023		RX	Yes	No					Y
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-003	Feb 17, 2023		RX	Yes	Yes					Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-001	Apr 3, 2017		RX	Yes	No					Y

International Family Members for US Patent 8,524,733

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009303758
Brazil	PI0913457
Canada	2736409
Canada	2972242